FDA Approved: JYLAMVO — Supplemental Application (SHORLA ONCOLOGY INC.)

View source ↗

Summary

The FDA approved a supplemental application for JYLAMVO (methotrexate) filed by SHORLA ONCOLOGY INC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Breast Cancer
• Choriocarcinoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• JYLAMVO (METHOTREXATE)

Snippet

SUPPL AP for JYLAMVO (METHOTREXATE)